93434-64-1

Basic information

• Product Name: methyl 2-(biphenyl-4-yloxy)propanoate
• Synonyms: propanoic acid, 2-([1,1'-biphenyl]-4-yloxy)-, methyl ester
• CAS NO: 93434-64-1
• Molecular Formula: C₁₆H₁₆O₃
• Molecular Weight: 256.2964
• Mol File: 93434-64-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 374.9°C at 760 mmHg
• Flash Point: 157.3°C
• Density: 1.104g/cm³
• Vapor Pressure: 8.09E-06mmHg at 25°C
• Refractive Index: 1.542
• CAS DataBase Reference: methyl 2-(biphenyl-4-yloxy)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(biphenyl-4-yloxy)propanoate(93434-64-1)
• EPA Substance Registry System: methyl 2-(biphenyl-4-yloxy)propanoate(93434-64-1)

Safety Data

• Hazardous Substances Data: 93434-64-1(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 5555-13-5 (+/-)-α-(4-Biphenyloxy)-propionsaeure 
• 5445-17-0 Methyl 2-bromopropionate 
• 92-69-3 4-Phenylphenol 

Relevant articles and documents

An exit beyond the pharmacophore model for 5-HT6R agents - a new strategy to gain dual 5-HT6/5-HT2A action for triazine derivatives with procognitive potential

This research allowed us to find the first highly potent 5-HT6/5-HT2A receptor (5-HT6/5-HT2AR) dual antagonists in a group of 1,3,5-triazine compounds as a result of an exit beyond the hydrophobic feature of the pharmacophore model for 5-HT6R antagonists. Design and synthesis of the series (2–16) of new O- and S-containing ether derivatives of 1,3,5-triazines with the double-ring aromatic region have been performed. The new compounds were examined within the comprehensive pharmacological screening, including: radioligand binding assays, functional and ADMET studies in vitro as well as behavioral tests in rats. Crystallographic aspects and computer-aided structure–activity relationship were analyzed, as well. The comprehensive approach led to selection of compound 12 (4-(4-methylpiperazin-1-yl)-6-(2-(naphthalen-2-ylthio)propan-2-yl)-1,3,5-triazin-2-amine) with the most significant dual 5-HT6/5-HT2AR antagonistic action (5-HT6R Ki = 11 nM, 5-HT2AR Ki = 39 nM). Moreover, the compound 12 has satisfactory ADMETox properties in vitro, i.e.: the high permeability through biological membranes, high metabolic stability, neither mutagenic nor hepatotoxic effects, and moderate ability to inhibit CYP3A4. Above all, 12 showed ability to reverse the pharmacologically-induced (MK-801) memory impairment at low doses (1–3 mg/kg) in Novel Object Recognition (NOR) test in rats. Our results indicate a promising potency of dual 5-HT6/5-HT2AR antagonism in the search for novel strategy to fight Alzheimer's disease, which remains an unmet clinical need.